RaQualia Pharma to absorb wholly-owned subsidiary Temric

RaQualia Pharma has decided to absorb Temric Co., Ltd. in an absorption-type merger effective January 1, 2026. This move aims to improve operational efficiency for the RaQualia Group, reduce costs, and simplify and enhance management tasks.

As a simplified absorption-type merger involving a wholly-owned subsidiary, no new shares will be issued, and no merger consideration will be paid. RaQualia Pharma will be the surviving company, while Temric, a cancer-focused drug discovery company, will be dissolved. This merger is expected to have a minor impact on RaQualia Pharma's consolidated performance.

Temric Co., Ltd., established on January 25, 2002, had a capital of 10 million yen. Its total assets were 340 million yen, and net assets were 337 million yen as of December 2024. For the same period, RaQualia Pharma reported total assets of 9,655 million yen and net assets of 5,570 million yen.